Market Report Source

Overview

Introduction
Allergic rhinitis affects between 15% and 20% of the population in the seven major markets. Currently available treatments focus on symptom relief; however, a significant number of allergic rhinitis patients with uncontrolled symptoms remain. Shorter, safer, and more convenient therapies currently in development may lead to a substantial market expansion.

Scope
Detailed break-down of the prevalence of allergic rhinitis by country, severity and type of allergen
Evaluation of current strategies for the treatment of this disease, including the current role of immunotherapy
Analysis of future trends in immunotherapy
Assessment of the potential for new immunotherapies

Highlights
The prevalence of allergic rhinitis in the seven major markets ranges from 7.9% (Spain) to 17.2% (France), but only about half of the affected population currently seek treatment.

Immunotherapy is dominated by a few regional players, constituting a small niche within the EUR 16 billion allergic rhinitis market.

Several small companies are developing immunotherapy products with likely competitive advantages over currently available products. The aim is to achieve shorter sublingual immunotherapy courses.

Reasons to Purchase
Identify the most lucrative targets for immunotherapeutic product development strategies in allergic rhinitis
Detailed breakdown of the prevalence of allergic rhinitis according to country, severity and allergen
Gain competitive advantages when positioning new immunotherapies for allergic rhinitis

Table of Contents

TABLE OF CONTENTS

CHAPTER 1 EXECUTIVE SUMMARY

Scope

Datamonitor insight into the disease market

CHAPTER 2 DISEASE BACKGROUND

Disease classification and epidemiology

Prevalence of AR

Historic trends in AR prevalence show increase

Costs of AR

Etiology

Minimal persistent inflammation

Symptoms and co-morbidities

Asthma is main and most important co-morbidity

Diagnosis

CHAPTER 3 TREATMENT OPTIONS

Immunotherapy

Immunotherapy: an expanding market?

CHAPTER 4 FUTURE TRENDS IN IMMUNOTHERAPY

CHAPTER 5 REFERENCES